Ovid Therapeutics - OVID Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View OVID analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month price objectives for Ovid Therapeutics' shares. Their OVID share price forecasts range from $2.50 to $2.50. On average, they predict the company's share price to reach $2.50 in the next year. This suggests a possible upside of 35.1% from the stock's current price.
View analysts price targets for OVID or view top-rated stocks among Wall Street analysts.

Ovid Therapeutics' stock was trading at $3.21 at the start of the year. Since then, OVID shares have decreased by 42.4% and is now trading at $1.85.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our OVID earnings forecast.

Ovid Therapeutics Inc. (NASDAQ:OVID) issued its earnings results on Tuesday, November, 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.01 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Rubric Capital Management LP (6.41%), Vanguard Group Inc. (3.66%), Stonepine Capital Management LLC (2.19%), BlackRock Inc. (1.64%), Dimensional Fund Advisors LP (0.06%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin.
View institutional ownership trends.

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OVID stock can currently be purchased for approximately $1.85.

Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $130.37 million and generates $208.38 million in revenue each year. The company earns $122.83 million in net income (profit) each year or ($0.99) on an earnings per share basis.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com.